Clopidogrel with or without Omeprazole in Coronary Artery Disease

Bhatt, Deepak L.; Cryer, Byron L.; Contant, Charles F.; Cohen, Marc; Lanas, Angel; Schnitzer, Thomas J.; Shook, Thomas L.; Lapuerta, Pablo; Goldsmith, Mark A.; Laine, Loren; Scirica, Benjamin M.; Murphy, Sabina A.; Cannon, Christopher P.
November 2010
New England Journal of Medicine;11/11/2010, Vol. 363 Issue 20, p1909
Academic Journal
Background: Gastrointestinal complications are an important problem of antithrombotic therapy. Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy. Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel. Methods: We randomly assigned patients with an indication for dual antiplatelet therapy to receive clopidogrel in combination with either omeprazole or placebo, in addition to aspirin. The primary gastrointestinal end point was a composite of overt or occult bleeding, symptomatic gastroduodenal ulcers or erosions, obstruction, or perforation. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, revascularization, or stroke. The trial was terminated prematurely when the sponsor lost financing. Results: We planned to enroll about 5000 patients; a total of 3873 were randomly assigned and 3761 were included in analyses. In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001). The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P=0.001). A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P=0.96); high-risk subgroups did not show significant heterogeneity. The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole. Conclusions: Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding. There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI. (Funded by Cogentus Pharmaceuticals; ClinicalTrials.gov number, NCT00557921.) N Engl J Med 2010;363:1909-17.


Related Articles

  • Influence of different proton pump inhibitors on platelet function in acute myocardial infarction patients receiving clopidogrel treatment after percutaneous coronary intervention. Zhe Wang; Xinchun Yang; Jun Cai; Mulei Chen; Xinhong Wan // Biomedical Research (0970-938X);2013, Vol. 24 Issue 4, p453 

    The objective of the present study is to investigate the effect of clopidogrel and proton pump inhibitors (PPIs) on upper gastrointestinal bleeding and adverse cardiovascular events in acute myocardial infarction (MI) patients after percutaneous coronary intervention (PCI). A total of 240...

  • Interventional Cardiology. Fish, R. David // Texas Heart Institute Journal;2010, Vol. 37 Issue 3, p309 

    The article describes developments in primary percutaneous coronary intervention (PCI). Particular focus is given on primary PCI for acute myocardial infarction, antiplatelet drugs and strategies and proton pump inhibitors and clopidogrel. It presents an overview of the clinical trial of the...

  • Drug-Drug Interaction Profiles of Proton Pump Inhibitors. Ogawa, Ryuichi; Echizen, Hirotoshi // Clinical Pharmacokinetics;2010, Vol. 49 Issue 8, p509 

    Proton pump inhibitors (PPIs) are widely prescribed for the treatment of gastric acid-related disorders and the eradication of Helicobacter pylori. In addition, they are routinely prescribed for the prevention of gastrointestinal bleeding in patients receiving a dual antiplatelet therapy...

  • The Importance of High-Quality Evidence of the Long-Term Impact of Nonfatal Events Used in Randomized Controlled Trials: A Case Study of Prasugrel. Lu, C. Y.; Karnon, J.; Sorich, M. J. // Clinical Pharmacology & Therapeutics;Jul2011, Vol. 90 Issue 1, p27 

    Randomized controlled trials (RCTs) are the centerpiece of evidence-based medicine. However, because of the limited follow-up, additional evidence on the long-term consequences of the outcomes used in trials is commonly required for clinical and policy decision making. This article provides...

  • Antiplatelets and PPIs top sellers in first quarter 2012.  // PharmacoEconomics & Outcomes News;8/4/2012, Issue 659, p11 

    The article reports on the increase in sales of antiplatelet agent clopidogrel and proton pump inhibitor esomeprazole in the U.S. during the first quarter of 2012.

  • Predicting peri-procedural myocardial infarction during PCI. Meier, Pascal; Froehlich, Georg M.; Yellon, Derek M.; Hausenloy, Derek J. // Heart;Oct2012, Vol. 98 Issue 20, p1471 

    In this article, the authors reflect on an article based on a study concerning percutaneous coronary intervention (PCI). They commend the study for identifying patients at greatest risk for peri-procedural myocardial infarction (PMI) during PCI allowing new targeted treatment capable of reducing...

  • Anticoagulants/antiplatelets/antithrombotics.  // Reactions Weekly;5/8/2010, Issue 1300, p8 

    The article presents the case of a 38-year-old man with primary antiphospholid syndrome (APS) who developed intracerebral haematomas following treatment with various antithrombotics, anticoagulants and antiplatelets. Diagnosed with myocardial infarction, the patient received various drugs,...

  • Antithrombotics/paclitaxel/sirolimus.  // Reactions Weekly;9/25/2010, Issue 1320, p12 

    The article describes a case of fatal renal haemorrhage in a 54-year-old man following triple antiplatelet therapy with aspirin, clopidogrel and cilostazol, and oral anticoagulation therapy with warfarin after recurrent coronary stent thrombosis following drug-eluting and bare-metal stent...

  • Effects of New Antiplatelet Agents and Aldosterone Receptor Antagonists on Mortality in Patients with Myocardial Infarction. Eyuboglu, Mehmet // Cardiovascular Drugs & Therapy;Oct2015, Vol. 29 Issue 5, p495 

    A letter to the editor is presented in response to the article "Effects of New Antiplatelet Agents and Aldosterone Receptor Antagonists on Mortality in Patients With Myocardial Infarction," that was published in the previous issue.


Read the Article


Sign out of this library

Other Topics